Pacira pours up to $25M into surgical reconstruction player TELA Bio

The OviTex line of bioscaffolds is indicated for ventral hernia repair and abdominal wall reconstruction. (TELA Bio)

Pacira Pharmaceuticals has signed on to invest up to $25 million in TELA Bio, which markets a range of surgical scaffolds for the repair of abdominal hernias and reconstruction of the abdominal wall.

Specifically, the new injection of funds will boost the Malvern, Pennsylvania-based company’s clinical and commercial efforts in these two indications, said TELA CEO Antony Koblish in a statement.

“We also look forward to developing new OviTex products purposely designed for additional soft tissue procedures such as breast reconstruction,” Koblish said.


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

The OviTex suite of products includes reinforced bioscaffolds of varying sizes and thicknesses. They comprise biologic and synthetic materials in an embroidered construction that allows fluid and cells to move freely through it, the company says.

Under the agreement, Pacira will invest $15 million upfront, with another $10 million up for grabs if TELA meets certain performance thresholds.

“We believe the OviTex platform is a highly innovative and differentiated solution that is positioned to emerge as a leading surgical mesh that synergistically blends the strength of a synthetic with the regenerative properties of a biologic,” said Dave Stack, chairman and chief executive officer of Pacira Pharmaceuticals, in the statement. “Given the strong commercial overlap in soft tissue procedures between our two organizations, we look forward to identifying ways to further collaborate with TELA Bio over time.”

Suggested Articles

The FDA approved the first spinal tether to correct the most common form of scoliosis—a ropelike implant that pulls the vertebrae into shape.

Agilent launched a new analyzer for research that observes cell behavior in real time while also collecting biosensor information.

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy.